Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Martens-Latem – page 3

1 432 clinical trials in Sint-Martens-Latem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Martens-Latem at a glance
1 432
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 432 trials in Sint-Martens-Latem

Open in trial search

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Martens-Latem

What the registry says about research in the country

01 Musculoskeletal Diseases

Clinical research in Sint-Martens-Latem is focused on musculoskeletal diseases, with a strong emphasis on osteoarthritis and related joint pain. The studies are designed to better understand treatment options that may improve comfort and day-to-day function.

  • Knee osteoarthritis
  • Osteoarthritis
  • Testing new approaches to ease joint pain and support mobility

These trials aim to assess whether emerging therapies can offer meaningful relief for people living with chronic joint disease.

02 Nutritional and Metabolic Diseases

Another active area is nutritional and metabolic diseases, especially studies involving overweight and obesity. Research here is exploring whether new treatments can help with weight management while also addressing related health concerns.

  • Overweight or obesity
  • Evaluating therapies that may support healthier body weight
  • Looking at how metabolic treatment options may affect symptoms linked to joint disease

In addition to weight-related outcomes, the research also considers how these approaches may influence overall well-being in people with overlapping conditions.

03 Combined Osteoarthritis and Weight-Related Research

The clinical trial landscape also brings together osteoarthritis and obesity research, reflecting the close connection between excess body weight and knee pain. This combined focus is especially relevant for patients whose symptoms are affected by both joint and metabolic factors.

  • Knee osteoarthritis with overweight or obesity
  • Measuring changes in pain and physical comfort
  • Assessing whether a new therapy can support both symptom relief and weight-related outcomes

These studies aim to generate practical evidence on treatments that may address more than one aspect of the condition at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.